COMPANY OVERVIEW ($CYTO.V)

Cytophage Technologies (TSXV:CYTO) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization.

Committed to addressing the global challenge of antibiotic resistance, Cytophage advances innovative products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.

Stock Information

Shares Outstanding
53,753,346
Warrants

7,114,165

Options

5,188,875

Fully Diluted

66,045,386

Investment Highlights

  • Pioneers in bacteriophage solutions
  • First publicly listed bacteriophage company with a stated focus on both animal health and human health solutions
  • Diversified pipeline of near term commercial sales
  • De-risked, replicable technology
  • Strong leadership team combining experience in high profile research, finance and commercialization

Cytophage investor call recording

On July 9, 2024, Cytophage held its first Investor Call since going public earlier this year. If you weren’t able to attend, we can provide you with a recording of the call upon request.

Cytophage in the news

NEWS RELEASE

Cytophage Reports AGM Results and Announces Upcoming Investor Call

Winnipeg, June 27, 2024. Cytophage Technologies Ltd. (TSXV:CYTO) (“Cytophage” or the “Company”), the only publicly traded phage company that is focused on bacteriophage solutions for both animal health and human health, is pleased to report the results of its annual general meeting (the “AGM”) of shareholders held on June 25, 2024 in Toronto, ON.

Read More

NEWS RELEASE

Cytophage Expands Commercialization of Phage Products in Asian Poultry Market

Winnipeg, June 20, 2024. Cytophage Technologies Ltd. (TSXV:CYTO) (“Cytophage” or the “Company”), the only publicly traded phage company that is focused on bacteriophage solutions for both animal health and human health, announces that it has signed of a Letter of Intent (LOI) with a leading Pan-Asian industrial agrifood company headquartered in Singapore.

Read More

NEWS RELEASE

Cytophage CEO to Present at TEDx Winnipeg Event

Winnipeg, June 4, 2024. Cytophage Technologies Ltd. (TSXV:CYTO) (“Cytophage” or the “Company”), the only publicly traded phage company that is focused on bacteriophage solutions for both animal health and human health, is pleased to announce that its CEO Dr. Steven Theriault, is set to present at TEDx Winnipeg on June 6, 2024, at the Prairie Theatre Exchange.

Read More

Subscribe For Investor Alerts

CORPORATE PRESENTATION

Investor Contact Information

We can win the war against battlefield infection.
Cytophage was selected for the Defense Innovation Award 2019.

Winner of 2018 Nutreco Feed Tech Challenge
For our breakthrough innovation to help feed the world.

Swine Bacteriophage

We’re helping farmers meet the need and the demand for a healthier food chain.

Funded in part by the Canada and Manitoba governments through the Canadian Agricultural Partnership – Ag Action Manitoba Program. Learn more

Contact Us

Learn more about our bacteriophage solutions.

Cytophage Technologies Ltd. © 2019